English

MEDIGOO expands in Europe – Planning IPO with a listing in 2020

MEDIGOO’s solution to health concerns
 
MEDIGOO provides people with a quick response to their health concerns through rapid health tests and genetic tests. The current portfolio of over one hundred products can provide solutions to multiple target audiences. Consumers can test for diseases that are sensitive (sexually transmitted diseases) and ensure the importance of going to the doctor (CRP, Lyme’s disease both in Human and the Tick, Helicobacter known also as gastric ulcer). The most sold tests are the categories of sexually transmitted tests and drug tests. The tests are easy to use, the test results are quickly visible at home and the reliability is the same as in laboratory tests.
 
MEDIGOO products are supported by two trends: / Euromonitor / Consumer Trends, January 2019). https://blog.euromonitor.com/euromonitor-reveals-the-top-10-global-consumer-trends-in-2019/
 
Market Potential
 
The development of consumer responsibility for their own health and the development of self-testing products will take market share in the market for traditional laboratory testing services. The size of Laboratory Services MarketWatch has globally estimated 333 billion USD by 2023 (estimate August 2018). MEDIGOO’s goal is to offer self-test products to gain market share in this segment.
 
Commercialization
 
The company started large-scale commercialization of self-testing products in 2015. From now on, the distribution network has been expanded systematically and currently covers approximately half of Finnish pharmacies and products are also available in ten online stores in Finland, Britain, Spain and Germany. Medigoo.com site has over 20 000 visitors per month and over 50 000 pages views per month. Next, the online store is opening up in the Netherlands. Cumulative delivery volumes are currently 20,000 product packages by the end of February. The change in net sales by the end of 2018 has been over 300% since the end of 2017. In 2018, 90% of sales came from Finland and 10% from abroad. The sales target for 2019 is estimated between € 500,000 – € 1,000,000.
 
The goal of MEDIGOO is to increase sales in Finland (pharmacies, health shops) by marketing products to a wide audience. Equally important is to develop export distribution channels to the UK, Spain, Germany and the Netherlands.
 
Team expertise
 
MEDIGOO Oy’s operational core team has worked together for a long time. The team has expertise in sales, technology, financial management and international marketing. Key employees have previous experience in building e-commerce and managing business. The company’s Board of Directors has been approved during 2019 so that the Company has sufficient strategic and business management expertise. The members of the Board of Directors have a background in business and finance management, sales and marketing, which in its entirety strengthens MEDIGOO ‘s expertise and supports the management team’ s operational activities.
 

Dr. Mika Karilahti, CEO, has a long experience in Director roles at Nokia Sourcing, Samsung Sales, and additionally he has managed a Webhosting company and later sold that business to Nebula. Earlier he managed an accounting office and later sold its business to another accounting & auditing company. His skills are in the areas of Technology, Sourcing, Sales, and Financial accounting.

Mr. Teemu Polo, Chairman of the Board, has worked with and within startups since ~2004 and currently works at New Company Consulting unit (NewCo) run by the City of Helsinki in Finland. He is at his best with business development.

Ms. Pia Ali-Tolppa, Member of the Board, works as CEO at Bonum Bank Oy. She is bringing her competences in the Finance sector, IT, HR, Management accounting, Risk Control and Digitalisation. Her earlier employment has been VP at SEB, and CFO at Wello.

Ms. Riikka Friman, Member of the Board, works as Vice President, Digital and Content Marketing at F-Secure Oyj. Her experience is in brand management, sales development in digital and distribution channels. Her previous positions have been in brand management at Rautaruukki and Kemira.

Mr. Jussi Kivikari, Member of the Board, works as Development Director at The Finnish Fair Corporation. He brings experience in event marketing and B2B sales.

Mr. Mika Teikari, Member of the Board, works as Managing Director at Success Clinic Finland Oy. He has vast experience in B2B sales in the health sector.

For further information, please contact:
Timo Friman, CFO, E-mail: [email protected], Phone: +358 40 703 1439 (mobile)
Mika Karilahti, CEO, Email: [email protected], Phone: +358 400 350189 (mobile) and +44 7452 120298 (mobile) and +1 (917) 503 3941 (office)
 
By subscribing to shares and paying them, the subscriber agrees to this Shareholders Agreement: Shareholders-Agreement-Medigoo_2019-03-13

 

Subscription period:

14 March – 31 August 2019

Minimum subscription:

2 480,43 €    (2787 pcs shares) Crowdfunding platform will incur some additional costs to the share subscriber.

Minimum amount:

No minimum, the issuance of the shares shall commence without any cancellations, all subscriptions above minimum subscription will be executed.

Maximum amount:

2 000 000 €    (2 229 927 pcs shares )

Emission organizer:

Medigoo Oy Inc.

Aftermarket

Company shares are being moved into the Finland Euroclear maintained ownership register, but they are not yet being traded on any regulated marketplace or multi-marketplace. There is currently no working aftermarket. In the Euroclear system the shareholder is required to open a holding account with a local bank or trader in Finland. Foreign investors shall be using the nominee register system.

Issuer

Medigoo Oy Inc.

Investment yield

Investor can obtain yield with the increase of the share valuation, aiming towards First North stock listing in 2020.

Investment type

High risk investment to growth company common stock carrying voting rights.

Offered equity

25 % (with the assumption of fully subscribed share emission).

Company valuation

In the Company’s view, the company valuation before the issuance of the shares is EUR 6,000,000. The Company valuation after the issuance of the shares is EUR 8,000,000 if the issuance is fully exercised. The valuation has been calculated by indicating the total amount of the Company shares, stock options and other rights entitling to shares at the commencement of the Offering at the subscription price used in connection with the Offering.

Share type

Medigoo Oy has only one class of shares in use. All the shares on the date of the marketing attachment belong to the same class of common stock.